 |
|
|
|
 |
|
|
| Article 1 to 9 out of 9 concerning Pharming Group N.V.
|
-
Dnage to Participate in European Study on Biomarkers of Ageing
(07/16/2008)
Biotech company Pharming Group NV announced that its wholly owned subsidiary DNage is participating in a large European study, called MARK-AGE, to identify and establish biomarkers of human ageing. Under the Seventh Research Framework Programme ...
-
Pharming announces positive results from North American randomized trial with rhucin
(06/18/2008)
Pharming Group N.V. announced positive safety and efficacy results from its North American trial with RhucinŽ (recombinant human C1 inhibitor) for the acute treatment of Hereditary Angioedema (HAE). The positive results with both primary and ...
-
Pharming concludes license agreement with Advanced Cell Technology
(03/03/2008)
Company further strengthens transgenic technology platform
Pharming Group NV announced that it has concluded a license agreement with Advanced Cell Technology Inc to obtain exclusive rights on patents in the field of transgenic technology, to which it already had non-exclusive rights. Financial details of ...
-
Pharming receives funding for development of new treatments for premature ageing diseases
(01/29/2008)
Pharming Group NV announced that its wholly owned subsidiary DNage will head a collaborative Research and Development effort to identify novel biomarkers and therapeutic targets, and to develop therapeutics for the treatment of premature ageing ...
-
Pharming announces completion of randomized treatments in North American clinical trial with Rhucin
(10/31/2007)
Pharming Group N.V. announced that it has completed randomized treatments in its North American clinical trial assessing the safety and efficacy of RhucinŽ (recombinant human C1 inhibitor) to treat acute attacks of hereditary angioedema (HAE). The ...
-
Pharming receives Orphan Drug Designation for recombinant Fibrinogen from FDA
(10/15/2007)
Pharming Group N.V. announced that it has received Orphan Drug designation for recombinant human fibrinogen (rhFIB) from the US Food and Drug Administration (FDA) for the treatment of bleeding in patients deficient in fibrinogen. Pharming has ...
-
Pharming Receives Fast Track Designation From US FDA For Recombinant Human C1 Inhibitor
(08/01/2006)
Pharming Group NV announced that it has received a Fast Track designation on recombinant human C1 inhibitor (rhC1INH) for the treatment of hereditary angioedema (HAE) from the US Food and Drug Administration (FDA).There is no approved therapy ...
-
Public-private partnership in biomedical materials will give a boost to medical innovation and the Dutch knowledge-based economy
(05/18/2006)
Universities and companies joining forces to give the Netherlands a leading position in Biomedical Materials
A consortium of leading Dutch industrial companies, small and medium-sized companies, knowledge institutes and public organizations recently convened a meeting in the Dutch city of Den Bosch to confirm their partnership in the BioMedical Materials ...
-
DNage, Loders Croklaan, BG Medicine and Erasmus announce collaboration in the field of type II diabetes
(05/02/2006)
DNage BV, Loders Croklaan BV, through its wholly owned subsidiary Lipid Nutrition BV ("Lipid Nutrition"), BG Medicine Inc ("BG Medicine") and the Erasmus University Medical Center ("Erasmus MC") announced the start of a collaboration to develop new ...
Additional information
Pharming Group N.V.
Leiden, Netherlands
Company
|
|
|
|
|
|
Top
